Type 2 inflammation is associated to a greater disease burden [3, 4] and is defined by tissue eosinophilia (≥ 10 eosinophils/high field power, blood eosinophilia (≥ 150 cells/μL and high level of serum total IgE (≥ 100 KU/L) and additional increased expression of T2 cytokines such as IL-4, IL-5, IL-13 [1, 5]. The gene discussed is IL13; the disease is Increased total eosinophil count.